Showing 8321-8330 of 9130 results for "".
- FDA Approves Sorilux for Adolescent Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-sorilux-for-adolescent-plaque-psoriasis/2460039/The FDA has approved Mayne Pharma Group Limited's Sorilux (calcipotriene) Foam, 0.005% in adolescents 12 years and older. The FDA approved Sorilux in 2010 based on evidence from two eight-week placebo controlled clinical trials in patients with mild to moderate plaque psoriasis of t
- Happy 10th Birthday Dysport!https://practicaldermatology.com/news/happy-10th-birthday-dysport/2460015/Galderma Laboratories’ Dysport (abobotulinumtoxinA) is ringing in its 10th birthday. To celebrate this milestone, Galderma is offering double points for Dysport aesthetic treatments registered in the ASPIRE Rewards program through July 31
- Ovation Science Appoints Medical Dermatology Advisory Boardhttps://practicaldermatology.com/news/ovation-science-appoints-medical-dermatology-advisory-board/2460008/Ovation Science, Inc. has entered into an exclusive agreement with Skincareguide.com Ltd., to act as the Company's Medical Dermatology Advisory Board for cannabis formulated products. The objective of the Medical Dermatology Advisory Board is to provide guidance, along with clinical, scientif
- FDA Approves AbbVie's Skyrizi for Psoriasishttps://practicaldermatology.com/news/fda-approves-abbvies-skyrizi-for-psoriasis/2460007/Skyrizi™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In clinical trials, Skyrizi prod
- Fibrocell to Collaborate with Castle Creek Pharmaceuticals to Develop and Commercialize RDEB Gene Therapyhttps://practicaldermatology.com/news/fibrocell-to-collaborate-with-castle-creek-pharmaceuticals-to-develop-and-commercialize-rdeb-gene-therapy/2460004/Fibrocell Science, Inc. has entered into a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, life-threatening genetic disord
- Maine Gets SUNucatedhttps://practicaldermatology.com/news/maine-gets-sunucated/2460001/Maine is joining 19 other states in allowing students to possess and use sunscreen in school. Governor Janet Mills signed LD 441, which was sponsored by Senator Cathy Breen. Modeled after American Society for Dermatologic Surgery Association’s (ASDSA) SUNucate legislation, the bil
- InMode Launches AccuTite, the Smallest RFAL Treatment for Face and Bodyhttps://practicaldermatology.com/news/inmode-launches-accutite-the-smallest-rfal-treatment-for-face-and-body/2460000/InMode Ltd
- A Conserved Stress Response May Fuel Resistance to BRAF Inhibitors in Melanomahttps://practicaldermatology.com/news/a-conserved-stress-response-may-fuel-resistance-to-braf-inhibitors-in-melanoma/2459999/Moffitt Cancer
- AAD Honors Dr. Robert Brodell for Establishing Free Clinic in the Mississippi Deltahttps://practicaldermatology.com/news/aad-honors-dr-robert-brodell-for-establishing-free-clinic-in-the-delta/2459998/Robert T. Brodell, MD, FAAD, is an American Academy of Dermatology (AAD) Patient Care Hero for working with colleagues at the University of Mississippi Medical Center in Oxford to open a dermatology clinic in the Delta — an area of the state that previously did not have a dermatologist for
- AIM at Melanoma Opens Melanoma Tissue Bank in the UShttps://practicaldermatology.com/news/aim-at-melanoma-opens-melanoma-tissue-bank-in-the-us/2459991/AIM at Melanoma celebrated the grand opening of the first branch of the International Melanoma Tissue Bank Consortium (IMTBC) at the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center. The Pittsburgh site is one of six global locations of the consortium. These six institutions